Does LENVATINIB Cause Focal segmental glomerulosclerosis? 19 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 19 reports of Focal segmental glomerulosclerosis have been filed in association with LENVATINIB (Lenvima). This represents 0.1% of all adverse event reports for LENVATINIB.
19
Reports of Focal segmental glomerulosclerosis with LENVATINIB
0.1%
of all LENVATINIB reports
0
Deaths
5
Hospitalizations
How Dangerous Is Focal segmental glomerulosclerosis From LENVATINIB?
Of the 19 reports, 5 (26.3%) required hospitalization.
Is Focal segmental glomerulosclerosis Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for LENVATINIB. However, 19 reports have been filed with the FAERS database.
What Other Side Effects Does LENVATINIB Cause?
Diarrhoea (4,262)
Hypertension (4,152)
Fatigue (3,603)
Decreased appetite (3,257)
Malignant neoplasm progression (2,929)
Nausea (2,492)
Blood pressure increased (2,228)
Vomiting (1,962)
Asthenia (1,643)
Malaise (1,602)
What Other Drugs Cause Focal segmental glomerulosclerosis?
TACROLIMUS (339)
MYCOPHENOLATE MOFETIL (181)
PREDNISONE (173)
CYCLOSPORINE (96)
METHYLPREDNISOLONE (81)
PREDNISOLONE (73)
RITUXIMAB (73)
BASILIXIMAB (67)
OMEPRAZOLE (60)
LANSOPRAZOLE (55)
Which LENVATINIB Alternatives Have Lower Focal segmental glomerulosclerosis Risk?
LENVATINIB vs LEPONEX
LENVATINIB vs LERCANIDIPINE
LENVATINIB vs LETAIRIS
LENVATINIB vs LETERMOVIR
LENVATINIB vs LETROZOLE